FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
This article was originally published in The Pink Sheet Daily
Executive Summary
Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.
You may also be interested in...
FDA Rejects Labopharm Appeal On Once-Daily Tramadol
Canadian drug maker says it plans to appeal to the next supervisory level at the FDA.
FDA Rejects Labopharm Appeal On Once-Daily Tramadol
Canadian drug maker says it plans to appeal to the next supervisory level at the FDA.
Labopharm May Conduct Additional Trial To Support Tramadol NDA
U.S. regulators questioned Labopharm’s statistical methods in a May 30 “approvable” letter, the opioid analgesic’s second.